NEW YORK (GenomeWeb News) - Molecular diagnostics company BG Medicine will collaborate with researchers in Denmark and use data from various cohort studies conducted in Copenhagen in its High Risk Plaque Initiative, the company said today.
 
The HRP is a research initiative begun by BG Medicine, Merck, AstraZeneca, and Philips that aims to develop diagnostic biomarkers that can predict heart attacks caused by myocardial infarction or by the rupture of atherosclerotic plaque as early as four years before they occur. 
 

Get the full story

This story is free
for registered users

Registering provides access to this and other free content.

Register now.

Already have an account?
Login Now.

Researchers suggest that genetic variations could influence the side effects people experience when using synthetic cannabinoids, the International Business Times reports.

An analysis has examined the makeup of researchers on Twitter and what they share, Nature News reports.

At Stat News, Jim Kozubek argues that the Broad Institute is pushing the boundary of what a nonprofit is.

In PNAS this week: gut microbes may affect honeybee weight, phenotype and gene expression changes in DiGeorge syndrome, and more.